Review
Pharmacology & Pharmacy
Lin Cheng
Summary: Adverse drug reactions, particularly SJS and TEN, are a significant public health concern with high mortality rates and ineffective treatment options. Factors such as infections, mutations in drug metabolic enzymes, and immune responses contribute to SJS/TEN development. Future research directions include epigenetics, metabolites, and regulatory T cells.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Hua-Ching Chang, Tsung-Jen Wang, Ming-Hsiu Lin, Ting-Jui Chen
Summary: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening diseases caused by drugs. The effectiveness of systemic immunomodulating treatments for SJS/TEN is still controversial, but cyclosporine and biologic anti-TNF-alpha have shown promising results. Combination treatments are also being explored. Large-scale randomized controlled trials are needed for more definitive evidence. Advances in understanding the pathogenesis of SJS/TEN may inspire the discovery of potential therapeutic targets.
Article
Medicine, General & Internal
Ekaterina A. Nikitina, Daria S. Fomina, Ulyana A. Markina, Sergey S. Andreev, Yuri V. Streltsov, Tatiana S. Kruglova, Marina S. Lebedkina, Alexander V. Karaulov, Maryana A. Lysenko
Summary: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare syndromes characterized by necrotic skin and mucosal lesions. Drug-induced mechanisms are the most common cause, with certain drugs posing a higher risk. There is no gold standard treatment, but TNF-α inhibitors have shown promise in SJS/TEN cases.
FRONTIERS IN MEDICINE
(2023)
Article
Dermatology
Ting-Jung Hsu, Hsu-Hang Yeh, Chih-Hung Lee, Kwei-Lan Liu
Summary: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are potentially fatal adverse drug reactions. The most common culprit drug is carbamazepine, which has a strong association with HLA-B*15:02. There is no statistically significant correlation between in-hospital stay and the average daily dose of corticosteroids.
INTERNATIONAL JOURNAL OF DERMATOLOGY
(2021)
Article
Dermatology
Pan Lv, Jiangxia Huang, Qianru Yang, Ting Yang, Xianwei Cao, Ougen Liu, Zhibin Zhang
Summary: This study analyzed the expression profiles of circRNAs in peripheral blood mononuclear cells of SJS/TEN patients and found a correlation between circRNA expression and disease severity. Specifically, hsa_circ_0083619 was identified as a potential indicator for SJS/TEN severity and a circRNA-miRNA-mRNA network was constructed. The study suggests that the hsa_circ_0083619/miR-18a-5p/BCL2L10 axis may play a role in the pathogenesis of SJS/TEN.
EXPERIMENTAL DERMATOLOGY
(2023)
Article
Dermatology
Yasmin Chia Chia Liew, Karen Jui Lin Choo, Choon Chiat Oh, Shiu Ming Pang, Yi Wei Yeo, Haur Yueh Lee
Summary: This study evaluated the differences between Mycoplasma-related and drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. The results showed no significant differences in baseline characteristics and extent of involvement, but significant differences in mortality rates between the two groups.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2022)
Review
Medicine, General & Internal
Eri Tsukagoshi, Yoichi Tanaka, Yoshiro Saito
Summary: Drug-related Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) are rare but severe adverse drug reactions, with predicting their onset remaining challenging. Pharmacogenomic information on drug labels may differ among countries, but CPIC guidelines provide a scientifically sound goal for future pharmacogenomic implementation.
FRONTIERS IN MEDICINE
(2021)
Article
Dermatology
E. J. Roberts, V. Melchionda, G. Saldanha, S. Shaffu, J. Royle, K. E. Harman
Summary: Toxic epidermal necrosis (TEN)-like lupus is a rare condition that occurs in patients with acute severe flares of systemic lupus erythematosus, characterized by epidermal loss and mucosal ulceration. This condition may resemble drug-induced Stevens-Johnson syndrome/TEN, but differs in the absence of a suitable culprit drug and the context of acute lupus, requiring early input from Rheumatologists for appropriate management.
CLINICAL AND EXPERIMENTAL DERMATOLOGY
(2021)
Letter
Dermatology
ShengYang Bertrand Lian, Choon Chiat Oh, Yi Wei Yeo, Haur Yueh Lee
Summary: This case series documents the incidence of various nail changes as a sequelae to Stevens-Johnson syndrome/toxic epidermal necrolysis.
Article
Dermatology
Rokea A. El-Azhary, Somaira Nowsheen, Lawrence E. Gibson, David J. DiCaudo
Summary: This study retrospectively assessed clinical characteristics and mortality rate of patients with Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) who developed disseminated intravascular coagulation (DIC). The incidence of DIC in patients with SJS/TEN was low but associated with increased mortality. Common triggers of SJS/TEN included drugs and infections, and early clinician awareness and aggressive intervention are crucial for preventing death.
INTERNATIONAL JOURNAL OF DERMATOLOGY
(2021)
Review
Ophthalmology
Gabor Toth, Andrea Lukacs, Frank Schirra, Gabor L. Sandor, Petra Killik, Otto A. Maneschg, Zoltan Z. Nagy, Nora Szentmary
Summary: The aim of the review article was to summarize the current literature on Stevens-Johnson syndrome (SJS) and its severe form, toxic epidermal necrolysis (TEN). SJS/TEN is a serious multi-system, immune-mediated, mucocutaneous disease with a high mortality rate and potential for ocular complications. Early diagnosis, timely amniotic membrane transplantation, and aggressive topical management are important for preventing long-term eye problems. Ophthalmologists should regularly examine patients in both the acute and chronic phases for comprehensive ophthalmic care.
OPHTHALMOLOGY AND THERAPY
(2023)
Review
Medicine, General & Internal
Ming-Hsiu Hsieh, Tomoya Watanabe, Michiko Aihara
Summary: SJS/TEN are serious conditions caused by medication and infections, with keratinocyte death believed to be the main pathomechanism. Treatment options such as corticosteroids and IVIG as immunomodulators can potentially improve the prognosis of SJS/TEN.
FRONTIERS IN MEDICINE
(2021)
Review
Pediatrics
Jingwei Liu, Haibo Yan, Chunfeng Yang, Yumei Li
Summary: This study reports a case of bronchiolitis obliterans associated with toxic epidermal necrolysis and summarizes the clinical characteristics, treatment, and prognosis of this complication. Stevens-Johnson syndrome/toxic epidermal necrolysis has a severe impact on multiple organs in patients. The prognosis of bronchiolitis obliterans in these patients is poor, with a mortality rate of 25%.
FRONTIERS IN PEDIATRICS
(2023)
Review
Dermatology
Lindsey J. Gaghan, Margaret M. Coates, Lauren N. Crouse, Jayson Miedema, Julie E. Mervak, Carolyn M. Ziemer
Summary: This article reports a case of photodistributed SJS/TEN and highlights the similarities with other cases reported in the literature. A literature review revealed 8 previously reported cases of photodistributed SJS or TEN in healthy individuals. Most of these cases were young women who had exposure to UV radiation 24 to 72 hours prior to the onset of symptoms.
Letter
Dermatology
Yi Liu, Qing Li, Chenyu Chu, Yin Zhou
Summary: This study highlights the importance of further exploring factors influencing the declining incidence rate of SJS/TEN, implementing interventions to reduce loss-of-life expectancy and healthcare costs, and analyzing its impact on quality of life. The findings underscore the significance of continuous efforts to minimize the burden of SJS/TEN and enhance patient care.
BRITISH JOURNAL OF DERMATOLOGY
(2023)
Article
Dermatology
Mari Wataya-Kaneda, Hiroshi Nagai, Yuuki Ohno, Hiroo Yokozeki, Yasuyuki Fujita, Hironori Niizeki, Kazue Yoshida, Masaaki Ogai, Yuichi Yoshida, Akihiko Asahina, Kazuyoshi Fukai, Chiharu Tateishi, Izumi Hamada, Tatsuro Takahata, Kenji Shimizu, Shigeki Shimasaki, Hiroyuki Murota
DERMATOLOGY AND THERAPY
(2020)
Letter
Dermatology
Yasuyuki Fujita, Miho Komatsu, San Eun Lee, Yoshihiro Kushida, Chihiro Nakayama-Nishimura, Wakana Matsumura, Shota Takashima, Satoru Shinkuma, Toshifumi Nomura, Naoya Masutomi, Makoto Kawamura, Mari Dezawa, Hiroshi Shimizu
JOURNAL OF INVESTIGATIVE DERMATOLOGY
(2021)
Letter
Dermatology
Y. Maya, Y. Fujita, T. Mizukami, T. Takei, S. Shimizu
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2021)
Letter
Dermatology
Y. Fujita, T. Nohara, S. Takashima, K. Natsuga, M. Adachi, K. Yoshida, S. Shinkuma, T. Takeichi, H. Nakamura, O. Wada, M. Akiyama, A. Ishiko, H. Shimizu
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2021)
Editorial Material
Medicine, General & Internal
Yuka Maya, Yasuyuki Fujita, Fumihiro Kodama, Satoko Shimizu
BMJ-BRITISH MEDICAL JOURNAL
(2021)
Article
Genetics & Heredity
Toshinari Miyauchi, Shotaro Suzuki, Masae Takeda, Jin Teng Peh, Masayuki Aiba, Ken Natsuga, Yasuyuki Fujita, Takuya Takeichi, Taiko Sakamoto, Masashi Akiyama, Hiroshi Shimizu, Toshifumi Nomura
Summary: Revertant mosaicism, or natural gene therapy, refers to the spontaneous in vivo reversion of an inherited mutation in a somatic cell. In the case of heterozygous pathogenic CARD14 mutations causing autoinflammatory skin diseases, including psoriasis and pityriasis rubra pilaris, they are repaired mainly via homologous recombination. Mutant CARD14 alters the replication stress response and preferentially drives break-induced replication (BIR), shedding light on a previously undescribed role of BIR in genetic diseases.
AMERICAN JOURNAL OF HUMAN GENETICS
(2021)
Letter
Medicine, General & Internal
Yuka Maya, Yasuyuki Fujita, Takuya Mizukami, Satoko Shimizu
AMERICAN JOURNAL OF MEDICINE
(2021)
Letter
Dermatology
Yuka Maya, Yasuyuki Fujita, Takuya Mizukami, Sari Iwasaki, Satoko Shimizu
JOURNAL OF DERMATOLOGY
(2021)
Article
Cell Biology
Manao Kinoshita, Youichi Ogawa, Natsumi Hama, Inkin Ujiie, Akito Hasegawa, Saeko Nakajima, Takashi Nomura, Jun Adachi, Takuya Sato, Schuichi Koizumi, Shinji Shimada, Yasuyuki Fujita, Hayato Takahashi, Yoshiko Mizukawa, Takeshi Tomonaga, Keisuke Nagao, Riichiro Abe, Tatsuyoshi Kawamura
Summary: In the early stages of SJS/TEN, neutrophils trigger inflammation in a drug-specific manner by forming NETs and inducing necroptosis of keratinocytes. This process is unique to SJS/TEN and involves a cascade of events mediated by both innate and adaptive immune responses, potentially leading to diagnostic markers or therapeutic targets for these adverse drug reactions.
SCIENCE TRANSLATIONAL MEDICINE
(2021)
Letter
Dermatology
Yuka Maya, Yasuyuki Fujita, Kodai Miyamoto, Machiko Nishimura, Sari Iwasaki, Satoko Shimizu
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT
(2022)
Article
Dermatology
Misaki Kase, Yasuyuki Fujita, Asako Ota, Satoko Shimizu, Saori Itoi-Ochi, Shigetoshi Sano
Summary: Immune checkpoint inhibitors (ICI) have shown great therapeutic benefits for cancer patients, but can also lead to immune-related adverse events (irAE). This study presents three cases of cancer patients with cutaneous irAE, including altered histological features characterized by loss of Langerhans cells (LC), possibly due to hyperactivation of effector T cells mediated by ICI.
JOURNAL OF DERMATOLOGY
(2022)
Letter
Dermatology
T. Sugai, Y. Fujita, E. Inamura, Y. Maya, S. Shimizu
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2022)
Editorial Material
Pediatrics
Tatsuro Sugai, Yasuyuki Fujita, Souichi Yamada, Shuetsu Fukushi, Emi Inamura, Kinya Hatakeyama, Satoko Shimizu
JOURNAL OF PEDIATRICS
(2022)
Article
Dermatology
Yasuyuki Fujita, Tatsuro Sugai, Yuka Maya, Emi Inamura, Yoko Hirano, Satoko Shimizu
Summary: Lichen planus is a chronic disorder involving T-cell-mediated reactions and changes in the oral mycobiome. A case study of a patient with psoriatic arthritis treated with secukinumab showed worsening of labial lichen planus but successful treatment of candidiasis. Switching to risankizumab, an anti-IL-23p19 agent, improved the patient's lichen planus without candidiasis recurrence. Anti-IL-23p19 agents may be a potential treatment for refractory lichen planus.
JOURNAL OF DERMATOLOGY
(2023)
Article
Dermatology
Hiroaki Iwata, Naoya Haga, Tatsuro Sugai, Yasuyuki Fujita
Summary: During biologic treatments, only infliximab was found to significantly increase serum KL-6 levels. Elevated serum KL-6 levels were more common in the infliximab group, with no pulmonary changes observed in patients with elevated KL-6 levels.
JOURNAL OF DERMATOLOGY
(2021)